Profile data is unavailable for this security.
About the company
MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
- Revenue in EUR (TTM)203.50m
- Net income in EUR-456.34m
- Incorporated1998
- Employees464.00
- LocationMorphoSys AGSemmelweisstr. 7PLANEGG 82152GermanyDEU
- Phone+49 89899270
- Fax+49 8 989927222
- Websitehttps://www.morphosys.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Puretech Health PLC | 3.07m | -60.63m | 526.47m | 90.00 | -- | 1.40 | -- | 171.32 | -0.1841 | -0.1841 | 0.0093 | 1.33 | 0.0048 | -- | 0.4676 | 28,888.12 | -9.54 | 4.92 | -10.67 | 5.94 | -- | -- | -2,000.84 | 352.67 | -- | -- | 0.0524 | 0.00 | -78.68 | -30.64 | -30.47 | -- | -44.10 | -- |
Basilea Pharmaceutica AG Allschwil | 162.30m | 10.76m | 538.32m | 147.00 | 45.30 | -- | 43.39 | 3.32 | 0.8765 | 0.8765 | 13.15 | -0.8335 | 0.7999 | 1.06 | 5.16 | 1,072,340.00 | 5.30 | -1.86 | 7.69 | -2.99 | 83.00 | 83.45 | 6.63 | -2.99 | 2.64 | 2.02 | 1.10 | -- | 6.68 | 3.53 | -13.96 | -- | 11.17 | -- |
Philogen SpA | 23.13m | -6.16m | 599.48m | 160.00 | -- | 9.12 | -- | 25.92 | -0.1551 | -0.1551 | 0.5747 | 2.25 | 0.1887 | 6.65 | 7.95 | 144,562.50 | -5.03 | -7.32 | -5.56 | -8.36 | 40.04 | 32.04 | -26.64 | -58.66 | 6.84 | -- | 0.1414 | -- | -2.46 | 10.80 | -14.60 | -- | 51.78 | -- |
Abivax SA | 0.00 | -147.74m | 784.09m | 40.00 | -- | 4.00 | -- | -- | -3.35 | -3.35 | 0.00 | 3.12 | 0.00 | -- | -- | 0.00 | -73.79 | -65.49 | -96.88 | -94.75 | -- | -- | -- | -- | -- | -8.05 | 0.2206 | -- | -- | -- | -111.52 | -- | -19.06 | -- |
Formycon AG | 77.70m | 75.80m | 988.79m | 238.00 | 11.92 | 1.79 | 12.73 | 12.73 | 4.70 | 4.70 | 4.84 | 31.32 | 0.0891 | 104.80 | 3.56 | 326,453.80 | 8.69 | 5.87 | 9.33 | 6.33 | 30.00 | 28.54 | 97.55 | 39.76 | 0.9621 | -0.0189 | 0.0176 | 0.00 | 82.83 | 12.47 | 110.59 | 60.58 | 81.87 | -- |
Genus plc | 795.57m | 39.48m | 1.36bn | 3.48k | 34.59 | 2.01 | 14.97 | 1.71 | 0.5053 | 0.5053 | 10.18 | 8.71 | 0.6478 | -- | 6.03 | 193,642.10 | 2.90 | 3.58 | 3.30 | 4.20 | -- | -- | 4.47 | 5.44 | 1.40 | 5.44 | 0.3377 | 60.86 | 16.23 | 7.96 | -18.58 | 26.70 | 9.36 | 4.24 |
AddLife AB | 862.56m | 6.95m | 1.38bn | 2.29k | 205.46 | 3.14 | 15.42 | 1.60 | 0.6483 | 0.6483 | 80.41 | 42.38 | 0.7393 | 3.62 | 5.53 | 4,258,149.00 | 0.6112 | 5.31 | 0.9299 | 8.83 | 37.16 | 36.89 | 0.8267 | 5.79 | 0.4778 | 1.48 | 0.5173 | 31.73 | 6.62 | 31.30 | -60.42 | 8.00 | 44.43 | -1.89 |
BioArctic AB | 22.20m | -10.76m | 1.43bn | 90.00 | -- | 19.64 | -- | 64.49 | -1.38 | -1.38 | 2.86 | 11.24 | 0.2202 | -- | -- | 2,866,000.00 | -10.66 | 2.24 | -11.67 | 2.56 | 83.38 | 86.52 | -48.44 | 9.76 | -- | -- | 0.0043 | 0.00 | 169.83 | -2.91 | 2,150.71 | -9.69 | 11.83 | -- |
Gubra A/S | 27.49m | -5.97m | 1.49bn | 219.00 | -- | 23.09 | -- | 54.23 | -2.91 | -2.91 | 13.51 | 29.44 | -- | -- | -- | 936,095.90 | -- | -- | -- | -- | 56.06 | -- | -21.72 | -- | -- | -- | 0.1296 | -- | 2.82 | -- | -1,133.04 | -- | -- | -- |
Galapagos NV | 293.40m | 30.71m | 1.53bn | 646.00 | 49.74 | 0.5276 | -- | 5.21 | 0.466 | 4.23 | 4.45 | 43.93 | 0.0653 | 0.1892 | 6.11 | 454,184.20 | 0.6829 | -1.48 | 0.7594 | -1.65 | 123.06 | -- | 10.47 | -14.42 | 9.70 | -- | 0.0028 | -- | 3.47 | -2.02 | 94.42 | -- | 7.04 | -- |
Evotec SE | 776.60m | -90.69m | 1.73bn | 5.06k | -- | 1.56 | -- | 2.22 | -0.5124 | -0.5124 | 4.39 | 6.24 | -- | -- | -- | 153,447.10 | -- | -0.0064 | -- | -0.0076 | 20.16 | 24.51 | -11.68 | -0.0178 | 1.79 | -2.09 | 0.3619 | 0.00 | 3.99 | 15.79 | 52.23 | -- | 50.62 | -- |
BB BIOTECH AG | 278.75m | 316.85m | 2.26bn | -- | 7.04 | 0.8768 | -- | 8.09 | 5.62 | 5.62 | 4.91 | 45.11 | 0.0998 | -- | -- | -- | 11.35 | 2.34 | 12.96 | 2.52 | 97.74 | 99.06 | 113.67 | 35.40 | -- | -- | 0.1223 | 217.78 | -57.97 | -37.98 | 42.26 | -- | -- | -8.09 |
MorphoSys AG | 203.50m | -456.34m | 2.55bn | 464.00 | -- | -- | -- | 12.53 | -12.54 | -12.65 | 5.79 | -6.95 | 0.1002 | 1.86 | 4.58 | 388,358.00 | -22.47 | -10.25 | -27.58 | -11.61 | 83.89 | 85.92 | -224.25 | -78.53 | 1.38 | -- | -- | -- | -14.37 | 25.53 | -25.60 | -- | 3.11 | -- |